#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17774	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2528	866.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1881	1881	T	1174	T,G,A	1171,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17774	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2528	866.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1615	1615	C	1142	C,G,A	1140,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17774	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2528	866.7	0	HET	.	.	.	G206A,T	.	206	206	G	637	637	G	1084	G,A,T	842,239,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30076	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3951	948.2	0	.	n	.	0	G996A	SNP	996	996	G	1528	1528	A	1214	A,G,T	663,550,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30076	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3951	948.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1869	1869	A	1251	A	1251	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30076	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3951	948.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2503	2503	C	1007	C,A	1006,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30076	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3951	948.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2577	2577	A	866	A,T	865,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30076	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3951	948.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3129	3129	C	1042	C,T,G	1040,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	27	2564	folP	852	852	99.88	folP.l15.c4.ctg.1	1910	167.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6574	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3752	218.4	1	SNP	p	S91F	0	.	.	271	273	TCC	759	761	TCC	253;254;255	T;C;C,T	253;254;253,2	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6574	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3752	218.4	1	SNP	p	D95N	0	.	.	283	285	GAC	771	773	GAC	261;261;261	G,T;A,C;C	260,1;259,2;261	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6574	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3752	218.4	1	SNP	p	D95G	0	.	.	283	285	GAC	771	773	GAC	261;261;261	G,T;A,C;C	260,1;259,2;261	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	2402	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1756	170.5	0	.	p	.	0	A39T	NONSYN	115	117	GCC	642	644	ACC	254;257;255	A;C;C,A	254;257;254,1	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	2402	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1756	170.5	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	840	842	CAC	319;318;322	C,A;A;C	318,1;318;322	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	2402	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1756	170.5	0	.	p	.	0	E117K	NONSYN	349	351	GAA	876	878	AAA	325;328;325	A;A;A	325;328;325	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	2402	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1756	170.5	1	SNP	p	G45D	0	.	.	133	135	GGC	660	662	GGC	260;264;264	G;G,T;C	260;263,1;264	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1460	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c17.ctg.1	1492	122.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3469	214.6	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1859	1861	GCA	277;278;279	G;C,T;A	277;277,1;279	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3469	214.6	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2342	2344	ATT	303;302;302	A,G,C;T;T	300,2,1;302;302	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3469	214.6	1	SNP	p	D86N	0	.	.	256	258	GAC	812	814	GAC	304;303;301	G;A;C	304;303;301	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3469	214.6	1	SNP	p	S87W	0	.	.	259	261	AGT	815	817	AGT	301;302;303	A;G;T	301;302;303	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3469	214.6	1	SNP	p	S87I	0	.	.	259	261	AGT	815	817	AGT	301;302;303	A;G;T	301;302;303	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3469	214.6	1	SNP	p	S87R	0	.	.	259	261	AGT	815	817	AGT	301;302;303	A;G;T	301;302;303	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3469	214.6	1	SNP	p	S88P	0	.	.	262	264	TCC	818	820	TCC	305;307;310	T,G;C;C,A	304,1;307;309,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5120	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3055	208.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1786	1788	GGC	277;278;276	G,A;G;C	276,1;278;276	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1477	1479	GCA	274;274;270	G,A;C,A;A,C	273,1;272,2;269,1	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1480	1482	ATC	269;271;274	A;T;C,A	269;271;273,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1492	1494	GTG	269;268;271	G,T,A;T,G;G,T	267,1,1;267,1;270,1	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1492	1494	GTG	269;268;271	G,T,A;T,G;G,T	267,1,1;267,1;270,1	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1996	1998	ACC	267;269;272	A;C;C,A	267;269;271,1	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2050	2052	GCG	263;260;263	G;C,A;G,C	263;258,2;262,1	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2050	2052	GCG	263;260;263	G;C,A;G,C	263;258,2;262,1	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2173	2175	GGT	248;246;248	G,T;G;T	247,1;246;247	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2182	2184	GGC	245;245;246	G;G;C	245;245;246	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4830	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2851	211.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2200	2202	CCG	260;264;264	C;C;G	259;264;264	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6712	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3611	231.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3026	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2281	165.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	830	830	C	213	C,G	212,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3254	porB1a	984	984	99.39	porB1a.l6.c17.ctg.1	1911	211.7	0	.	p	.	0	G41R	NONSYN	121	123	GGA	615	617	AGA	297;300;298	A,C;G;A,G,C	296,1;300;296,1,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3254	porB1a	984	984	99.39	porB1a.l6.c17.ctg.1	1911	211.7	0	.	p	.	0	K88E	NONSYN	262	264	AAA	756	758	GAA	293;294;297	G;A,C;A	293;293,1;297	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3254	porB1a	984	984	99.39	porB1a.l6.c17.ctg.1	1911	211.7	0	.	p	.	0	E89K	NONSYN	265	267	GAA	759	761	AAA	305;306;304	A;A,C;A	305;305,1;304	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3254	porB1a	984	984	99.39	porB1a.l6.c17.ctg.1	1911	211.7	0	.	p	.	0	D120N	NONSYN	358	360	GAC	852	854	AAC	283;283;284	A,T;A,T;C	282,1;282,1;284	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3254	porB1a	984	984	99.39	porB1a.l6.c17.ctg.1	1911	211.7	0	.	p	.	0	G133D	NONSYN	397	399	GGT	891	893	GAT	283;283;283	G;A;T	283;283;283	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11520	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5344	268.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2195	2197	CAT	325;323;324	C,A,T;A;T	320,3,1;323;324	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1832	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1279	176.8	1	SNP	p	V57M	0	.	.	169	171	GTG	639	641	GTG	299;299;297	G,T;T;G	298,1;299;297	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
